Anaptysbio (ANAB) EBIAT (2016 - 2025)
Anaptysbio (ANAB) has disclosed EBIAT for 10 consecutive years, with $49.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 327.75% year-over-year to $49.6 million, compared with a TTM value of -$13.2 million through Dec 2025, up 90.89%, and an annual FY2025 reading of -$13.2 million, up 90.89% over the prior year.
- EBIAT was $49.6 million for Q4 2025 at Anaptysbio, up from $15.1 million in the prior quarter.
- Across five years, EBIAT topped out at $49.6 million in Q4 2025 and bottomed at -$46.7 million in Q2 2024.
- Average EBIAT over 5 years is -$25.4 million, with a median of -$33.2 million recorded in 2022.
- The sharpest move saw EBIAT crashed 7488.34% in 2022, then surged 327.75% in 2025.
- Year by year, EBIAT stood at -$32.5 million in 2021, then increased by 18.82% to -$26.4 million in 2022, then crashed by 59.81% to -$42.2 million in 2023, then surged by 48.39% to -$21.8 million in 2024, then soared by 327.75% to $49.6 million in 2025.
- Business Quant data shows EBIAT for ANAB at $49.6 million in Q4 2025, $15.1 million in Q3 2025, and -$38.6 million in Q2 2025.